Controlled inactivation of recombinant viruses with vitamin B2

Journal of Virological Methods

Volumn 148, Issue 1-2, 2008, Pages 132-145

  Callahan, Shellie M ^a   Wonganan, Piyanuch ^a   Obenauer Kutner, Linda J ^b   Sutjipto, Suganto ^b   Dekker, Joseph D ^a   Croyle, Maria A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adeno associated virus; Adenovirus; Inactive control; Lentivirus; Psoralen; Riboflavin

Indexed keywords

BETA GALACTOSIDASE; CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; METHOXSALEN; RIBOFLAVIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LENTIVIRINAE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ULTRAVIOLET IRRADIATION; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; BETA-GALACTOSIDASE; DEPENDOVIRUS; GENES, REPORTER; HUMANS; LENTIVIRUS; LIVER; METHOXSALEN; MICROSCOPY, ELECTRON, TRANSMISSION; PHOTOSENSITIZING AGENTS; RATS; RIBOFLAVIN; VIRUS INACTIVATION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; LENTIVIRUS; RNA VIRUSES;

EID: 39149114091     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2007.10.027     Document Type: Article

References (55)

1. Auricchio A., Hildinger M., O'Connor E., Gao G.P., and Wilson J.M. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum. Gene Ther. 12 (2001) 71-76
2. Bethea D., Fullmer B., Syed S., Seltzer G., Tiano J., Rischko C., Gillespie L., Brown D., and Gasparro F.P. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J. Dermatol. Sci. 19 (1999) 78-88
3. Bloomfield V.A. Quasi-elastic light scattering applications in biochemistry and biology. Annu. Rev. Biophys. Bioeng. 10 (1981) 421-450
4. Borgland S.L., Bowen G.P., Wong N.C., Libermann T.A., and Muruve D.A. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappa B. J. Virol. 74 (2000) 3941-3947
5. Brange J., Andersen L., Laursen E.D., Meyn G., and Rasmussen E. Toward understanding insulin fibrillation. J. Pharm. Sci. 86 (1997) 517-525
6. Braun A., Kwee L., Labow M.A., and Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 14 (1997) 1472-1478
7. Callahan S.M., Boquet M.P., Ming X., Brunner L.J., and Croyle M.A. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. J. Gene Med. 8 (2006) 566-576
8. Callahan S.M., Ming X., Lu S.K., Brunner L.J., and Croyle M.A. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J. Pharmacol. Exp. Ther. 312 (2005) 492-501
9. Cardo L.J., Rentas F.J., Ketchum L., Salata J., Harman R., Melvin W., Weina P.J., Mendez J., Reddy H., and Goodrich R. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang. 90 (2006) 85-91
10. Corbin F. Pathogen inactivation of blood coponents: current status and introduction of an approach using riboflavin as a photosensitizer. Int. J. Hematol. 76 (2002) S253-S257
11. Cotten M., Saltik M., Kursa M., Wagner E., Maass G., and Birnstiel M.L. Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Virology 205 (1994) 254-261
12. Cotten M., Wagner E., Zatloukal K., Phillips S., Curiel D.T., and Birnstiel M.L. High-efficiency receptor-mediated delivery of small and large kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 6094-6098
13. Croyle M.A., Anderson D.J., Roessler B.J., and Amidon G.L. Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery. Pharm. Dev. Technol. 3 (1998) 365-372
14. Croyle M.A., Callahan S.M., Auricchio A., Schumer G., Linse K.D., Wilson J.M., Brunner L.J., and Kobinger G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78 (2004) 912-921
15. Dardare N., and Platz M.S. Binding affinities of commonly employed sensitizers of viral inactivation. Photochem. Photobiol. 75 (2002) 561-564
16. Day R.S., and Ziolkowski C.H. Human adenoviruses as indicators of inhibition of DNA repair. Nucleic Acids Symp. Ser. (1984) 279-290
17. Day R.S., Giuffrida A.S., and Dingman C.W. Repair by human cells of adenovirus-2 damaged by psoralen plus near ultraviolet light treatment. Mutat. Res. 33 (1975) 311-320
18. Fouin-Fortunet H., Tinel M., Descatoire V., Letteron P., Larrey D., Geneve J., and Pessayre D. Inactivation of cytochrome P-450 by the drug methoxsalen. J. Pharm. Exp. Ther. 236 (1986) 237-247
19. Gerba C.P., Gramos D.M., and Nwachuku N. Comparative inactivation of enteroviruses and adenovirus 2 by UV light. Appl. Environ. Microbiol. 68 (2002) 5167-5169
20. Guo L.Q., and Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol. Sin. 25 (2004) 129-136
21. Hijnen W.A., Beerendonk E.F., and Medema G.J. Inactivation credit of UV radiation for viruses, bacteria and protozoan (oo)cysts in water: a review. Water Res. 40 (2006) 3-22
22. Ho P.C., Savillem D.J., and Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharmaceut. Sci. 4 (2001) 217-227
23. Kafri T., Morgan D., Krahl T., Sarvetnick N., Sherman L., and Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11377-11382
24. Klein H.G. Pathogen inactivation technology: cleansing the blood supply. J. Intern. Med. 257 (2005) 224-237
25. Konz J.O., Lee A.L., Lewis J.A., and Sagar S.L. Development of a purification process for adenovirus: controlling virus aggregation to improve the clearance of host cell DNA. Biotechnol. Prog. 21 (2005) 466-472
26. Kumar V., Lockerbie O., Keil S.D., Ruane P.H., Platz M.S., Martin C.B., Ravanat J., Cadet J., and Goodrich R.P. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem. Photobiol. 80 (2004) 15-21
27. Le H.T., Boquet M.P., Clark E.A., Callahan S.M., and Croyle M.A. Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose. Hum. Gene Ther. 17 (2006) 1095-1111
28. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K., Metzel P., and Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45 (2005) 580-590
29. Lu S.K., Callahan S.M., and Brunner L.J. Suppression of hepatic CYP3A1/2 and CYP2C11 by cyclosporine is not mediated by altering growth hormone levels. J. Pharmacol. Exp. Ther. 305 (2003) 331-337
30. Madge B.A., and Jensen J.N. Ultraviolet disinfection of fecal coliform in municipal wastewater: effects of particle size. Water Environ. Res. 78 (2006) 294-304
31. Mays D.C., Hilliard J.B., Wong D.D., and Gerber N. Activation of 8-methoxypsoralen by cytochrome P-450. Enzyme kinetics of covalent binding and influence of inhibitors and inducers of drug metabolism. Biochem. Pharmacol. 38 (1989) 1647-1655
32. Manickan E., Smith J.S., Tian J., Eggerman T.L., Lozier J.N., Muller J., and Byrnes A.P. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Molec. Ther. 13 (2006) 108-117
33. Nwachuku N., Gerba C.P., Oswald A., and Mashadi F.D. Comparative inactivation of adenovirus serotypes by UV light disinfection. Appl. Environ. Microbiol. 71 (2005) 5633-5636
34. No Authors Cited, The Journal of Gene Medicine Clinical Trials Worldwide Database [website] 2007 January 2007 [cited 2007 July 23]; http://www.wiley.co.uk/genetherapy/clinical/.
35. Obenauer-Kutner L.J., Halperin R., Ihnat P.M., Tully C.P., Bordens R.W., and Grace M.J. Use of an automated image processing program to quantify recombinant adenovirus particles. Microsc. Microanal. 11 (2005) 37-41
36. Obenauer-Kutner L.J., Ihnat P.M., Yang T.Y., Dovey-Hartman B.J., Balu A., Cullen C., Bordens R.W., and Grace M.J. The use of field emission scanning electron microscopy to assess recombinant adenovirus stability. Hum. Gene Ther. 13 (2002) 1687-1696
37. Osten P., Grinevich V., and Cetin A. Viral vectors: a wide range of choices and high levels of service. Handb. Exp. Pharmacol. 178 (2007) 177-202
38. Pathak M.A., and Fitzpatrick T.B. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J. Photochem. Photobiol. B 14 (1992) 3-22
39. Pelletier J.P., Transue S., and Snyder E.L. Pathogen inactivation techniques. Best Pract. Res. Clin. Haematol. 19 (2006) 205-242
40. Plant, N., 2006. The human cytochrome P450 sub-family: Transcriptional regulation, inter-individual variation and interaction networks. Biochim. Biophys. Acta (E-pub ahead of print).
41. Quick K., Gerding K., and Croyle M.A. Role of the container/closure system and formulation on agitation-induced aggregation phenomena in recombinant adenoviral products. Bioprocessing 2 (2003) 35-41
42. Ruane P.H., Edrich R., Gampp D., Keil S.D., Leonard R.L., and Goodrich R.P. Photochemical inactivation of selected viruses and bacteria platelet concentrates using riboflavin and light. Transfusion 44 (2004) 877-885
43. Sakurai, H., Kawabata, K., Sakurai, F., Nakagawa, S., Mizuguchi, H., 2007. Innate immune response induced by gene delivery vectors. Int. J. Pharm. (Epub ahead of print), doi:10.1016/j.ijpharm.2007.06.012.
44. Schnell M.A., Zhang Y., Tazelaar J., Gao G., Yu Q.C., Qia R., Chen S., Varnavski A., LeClair C., Raper S.E., and Wilson J.M. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3 (2001) 708-722
45. Seghatchian J., and de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus. Apher. Sci. 35 (2006) 189-196
46. Smith J.S., Tian J., Lozier J.N., and Byrnes A.P. Severe pulmonary pathology after intravenous administration of adenovirus vectors in cirrhotic rats. Mol. Ther. 9 (2004) 932-941
47. Templeton M.R., Andrews R.C., and Hofmann R. Inactivation of particle-associated viral surrogates by ultraviolet light. Water Res. 39 (2005) 3487-3500
48. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., and Lowenstein P.R. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7482-7487
49. Thornton C.A., and Ballow M. Safety of intravenous immunoglobulin. Arch. Neurol. 50 (1993) 135-136
50. Tinel M., Belghiti J., Descatoire V., Amouyal G., Letteron P., Geneve J., Larrey D., and Pessayre D. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem. Pharmacol. 36 (1987) 951-955
51. Tomazic-Jezic V.J., Merritt K., and Umbreit T.H. Significance of the type and size of biomaterial particles on phagocytosis and tissue distribution. J. Biomed. Mater. Res. 55 (2001) 523-529
52. Unna K., and Greslin J. Studies on the toxicity and pharmacology of riboflavin. J. Pharmacol. Exp. Ther. 75 (1942) 75-80
53. Wright J.F., Le T., Prado J., Bahr-Davidson J., Smith P.H., Zhen Z., Sommer J.M., Pierce G.F., and Qu G. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol. Ther. 12 (2005) 171-178
54. Wu Y.Y., and Snyder E.L. Safety of the blood supply: role of pathogen reduction. Blood Rev. 17 (2003) 111-122
55. Yang J., and Yan B. Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol. Sci. 95 (2007) 13-22